Smart ProTcell Smart Immune ProTcell: first-in-class allogeneic thymus empowered T cell therapy platform for fast and durable immune system reconstitution

Summary

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is used in immunodeficiencies & blood malignancies though costly, hard-to-access & linked to many severe complications. Smart Immune puts forth a high-profile solution to solve this gap: ProTcell platform supplies clinical-grade, allogeneic lymphoid progenitor cells produced in just 7 days ex-vivo. These are made into tolerant polyclonal mature T cells by the patient’s own thymus in a record 7 countries, we face a window opportunity. With the EIC’s support, we pursue the less attractive-to-VC’s SCID indication, as part of our Series A, to become a front row T-cell therapy player, with future chimeric antigen receptor (CAR) therapies in mind. We project to treat >40k patients by 2030 & recover a ROI of 5,28 over our target Series A.

Results, demos, etc. Show all and search (0)

Unfold all

Fold all

More information & hyperlinks

Web resources:	https://cordis.europa.eu/project/id/190102812
Start date:	01-06-2023
End date:	30-11-2025
Total budget - Public funding:	3 565 625,00 Euro - 2 495 937,00 Euro